Ionis Pharmaceuticals Announced Olezarsen 80 Mg Monthly Dose Met The Primary Endpoint Of Significantly Reducing Triglycerides In Patients With Genetically Validated Fcs At Six Months
Author: Charles Gross | April 07, 2024 10:08am
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events –
– Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S. –
– Data presented today at ACC 2024 and published in The New England Journal of Medicine –
– Ionis to host webcast on Monday, April 8 at 10:00 am ET –
Posted In: IONS